Read by QxMD icon Read

OncoTargets and Therapy

Takehiro Tozuka, Masahiro Seike, Yuji Minegishi, Shingo Kitagawa, Tomomi Kato, Natsuki Takano, Kakeru Hisakane, Satoshi Takahashi, Kenichi Kobayashi, Takeru Kashiwada, Teppei Sugano, Susumu Takeuchi, Shinobu Kunugi, Rintaro Noro, Yoshinobu Saito, Kaoru Kubota, Akihiko Gemma
Immuno-checkpoint inhibitors (ICI) have become an effective treatment option for non-small-cell lung cancer patients. However, ICI therapy was reported to be less effective in patients with epidermal growth factor receptor (EGFR) mutations than in those with wild-type EGFR. We report here that an non-small-cell lung cancer patient with the EGFR mutant T790M showed a programmed cell death ligand 1 (PD-L1) expression level that increased from <25% to >90% after eighth-line osimertinib therapy. He was treated with pembrolizumab as a ninth-line treatment, and attained stable disease...
2018: OncoTargets and Therapy
Minjun Liao, Pu Chen, Yan Liao, Jun Li, Wenmin Yao, Tian Sun, Weijia Liao, Lili Su
Background: At present, the predictive ability of the prognostic indicator of hepatocellular carcinoma (HCC) is still limited. This study aims to analyze the relationship between the preoperative high-sensitivity C-reactive protein to lymphocyte ratio (HCLR) and the clinicopathologic characteristics of HCC. Patients and methods: A total of 229 HCC patients undergoing surgical resection were retrospectively analyzed. The majority of the patients (132/229) had tumors larger than 5 cm, and 45 out of 229 had more than one tumor focus...
2018: OncoTargets and Therapy
Ying Chen, Ying Huang, Dong-Ming Chen, Chao Wu, Qiu-Ping Leng, Wen-Yi Wang, Ming-Qin Deng, Yan-Xia Zhao, Xiao-Hong Yang
Background: The usefulness of ribonucleotide reductase catalytic subunit M1 (RRM1) for predicting the therapeutic effects of gemcitabine-containing chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. RRM1-positive patients show unique clinicopathological features. Methods: Here, we performed a meta-analysis to systematically evaluate the relationship between RRM1 expression and the clinicopathological characteristics of NSCLC patients treated with gemcitabine-containing regimens...
2018: OncoTargets and Therapy
Wanjun Yu, Hao Jiang, Huihui Zhang, Jipeng Li
Background: Circular RNAs represent a new class of noncoding RNAs involved in the development of cancer. However, little is known about their role in non-small cell lung cancer (NSCLC). Methods: We examined hsa_circ_0003998 levels in 60 NSCLC tissues by quantitative real-time polymerase chain reaction and analyzed the clinicopathologic significance of hsa_circ_0003998 expression. The effect of small interfering RNA-mediated hsa_circ_0003998 knockdown on proliferation and invasion was analyzed in A549 and H1299 cells in vitro...
2018: OncoTargets and Therapy
Yuyi Wang, Li Tu, Chi Du, Xiaoxiao Xie, Yanyang Liu, Jiantao Wang, Zhixi Li, Ming Jiang, Dan Cao, Xi Yan, Feng Luo
Background: Breast cancer is the leading cause of mortality from cancer in women worldwide, and cancer stem-like cell (CSC) is responsible for failure treatment of breast cancer. It plays an important role in resistant disease and metastasis. CD44/CD24 and ALDH are well-accepted protein markers of breast CSC, and it was reported that distinct subtypes of breast CSC were identified by the 2 markers. It is possible that there are various kinds of breast CSC which could be identified by different markers, and CSC markers utilized at present are not enough to fully understand breast CSC...
2018: OncoTargets and Therapy
Yiyan Lei, Zhaoguo Liu, Weilin Yang
Background: The aim of this study was to observe the expression of microRNA-222 (miR-222) and matrix metalloproteinase inhibitor 3 (TIMP3) in non-small cell lung cancer (NSCLC) and discuss their significance. Methods: A total of 230 patients with NSCLC were enrolled in the observation group during the operation. Ninety-eight normal adjacent tissues were used as the control group. Two groups of miR-222 and TIMP3 were detected by in situ hybridization and immunohistochemistry...
2018: OncoTargets and Therapy
Jing Zhao, Ming Zou, Jinyan Lv, Yingmin Han, Guangzhi Wang, Gang Wang
Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation. However, the use of osimertinib may result in the development of further resistance, most commonly via the cis -C797S mutation. Herein, we report a case of a lung cancer patient harboring triple EGFR mutations of L858R, T790M, and cis -C797S who was treated with a combination of osimertinib, bevacizumab, and brigatinib...
2018: OncoTargets and Therapy
Guanghao Zhang, Yun Wu, Jiashu Zhang, Zhiqing Fang, Zhaoxu Liu, Zhonghua Xu, Yidong Fan
Objectives: The aim of this study was to establish comprehensive and practical nomograms, based on significant clinicopathological parameters, for predicting the overall survival (OS) and the disease-specific survival (DSS) of patients with clear cell renal cell carcinoma (ccRCC). Patients and methods: The data of 35,151 ccRCC patients, diagnosed between 2004 and 2014, were obtained from the database of the Surveillance, Epidemiology, and End Results (SEER) program...
2018: OncoTargets and Therapy
Lingqiong Zhao, Jie Liu, Shu Chen, Chun Fang, Xianquan Zhang, Zhibin Luo
Purpose: NANOG is a tumor marker and indicates poor prognosis in various neoplasms; however, the evidence is controversial. This meta-analysis investigated the association of NANOG expression and clinicopathological features, and it impact on survival of patients with malignant tumors. Methods: Studies published through May 31, 2018 were retrieved from PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure. Two researchers independently screened the content and quality of studies and extracted data...
2018: OncoTargets and Therapy
(no author information available yet)
[This corrects the article on p. 3493 in vol. 10, PMID: 28761358.].
2018: OncoTargets and Therapy
Li-Zhe Zhong, Hong-Yan Xu, Zhong-Min Zhao, Guang-Mei Zhang, Feng-Wu Lin
Objective: To evaluate the efficacy and safety of nedaplatin versus cisplatin in treating malignant pleural effusion (MPE) caused by cancers. Methods: The clinical data of 219 MPE patients treated from January 2013 to December 2016 were retrospectively reviewed. Intrapleural infusion with nedaplatin 80 mg/m2 (n=110) or with cisplatin 40 mg/m2 (n=109) were used as the treatment. Results: There was no significant difference in the overall response rate between the nedaplatin group (62...
2018: OncoTargets and Therapy
Keqiang Huang, Dongxu Liu
Background: Erlotinib is a commonly used molecular-targeted drug for the treatment of tongue cancer. However, the development of acquired resistance to erlotinib hampers its therapeutic use. Materials and methods: To analyze the erlotinib resistance, long-term and short term survival assay were used to compare the resistance between parental and resistant tongue cancer cells. Flow cytometry, Hochest staining and western blot were used to analyze the apoptosis among the cells...
2018: OncoTargets and Therapy
Peipei Liu, Wenhui Li, Yuanyuan Hu, Youhong Jiang
Background: Breast cancer is the most common fatal cancer in women worldwide. Previous studies have demonstrated that allograft inflammatory factor 1 like (AIF1L) plays a key role in mammary tumorigenesis, although the mechanism involved remains unclear. Purpose: The purpose of this study was to assess the clinicopathological and prognostic significance of AIF1L expression levels and biological function in breast cancer. Patients and methods: We used immunohistochemistry to detect the expression of AIF1L in breast cancer...
2018: OncoTargets and Therapy
Yingyu Liu, Changgui Kou, Wei Bai, Xinyu Liu, Yan Song, Lili Zhang, Mohan Wang, Yangyu Zhang, Yueyue You, Yue Yin, Xin Jiang, Ying Xin
Objectives: A Bayesian network meta-analysis (NMA) was conducted in patients with head and neck cancers (HNCs) to estimate the efficacy and safety of treatment with conventional fractionation radiotherapy (CF), conventional fractionation chemoradiotherapy (CF_CRT), hyperfractionated radiotherapy (HF), hyperfractionated chemoradiotherapy (HF_CRT), accelerated fractionation radiotherapy, accelerated fractionation chemoradiotherapy, accelerated hyperfractionated radiotherapy (HART) or accelerated hyperfractionated chemoradiotherapy (HACRT) to identify superior treatments to aid in clinical decisions...
2018: OncoTargets and Therapy
Orsolya Rusz, Renáta Kószó, Ágnes Dobi, Melinda Csenki, Erzsébet Valicsek, Alíz Nikolényi, Gabriella Uhercsák, Adrienne Cserháti, Zsuzsanna Kahán
Fulvestrant is a pure estrogen receptor (ER) antagonist approved for the treatment of metastatic ER positive breast cancer in postmenopausal women with disease progression following antiestrogen therapy. The clinical results of fulvestrant demonstrated encouraging activity in tumors in spite of HER2 positivity, but data about its use after progression on anti-HER2 agents are limited. Partial responses and durations of response of 12, 25, and 38 months in three cases with multiple metastases of ER positive and HER2 positive breast cancer were observed; all patients had been treated with 1-4 regimens of an anti-HER2 agent in combination with chemotherapy or an aromatase inhibitor before the initiation of fulvestrant...
2018: OncoTargets and Therapy
Guang-Lei Qiao, Li-Na Song, Zhou-Feng Deng, Ying Chen, Li-Jun Ma
Purpose: The prognostic value and clinical significance of CD44 variant isoform v6 (CD44v6) in breast cancer remains controversial. Our study aimed to generalize the correlation between CD44v6 expression and clinicopathological features and prognosis in breast cancer by using a meta-analysis. Methods: We performed a comprehensive search of relevant literature from PubMed, Cochrane Database, and EMBASE database that were published before January 2018. The pooled ORs and HRs with 95% CIs were used to estimate the effects...
2018: OncoTargets and Therapy
Lin Sang, Dawei Lu, Jun Zhang, Shihua Du, Xingbo Zhao
Purpose: The aim was to investigate mifepristone effects on endometrial carcinoma and the related mechanism. Methods: HHUA cells were treated with DMEM containing different concentrations of mifepristone. HHUA cells treated with 100 μmol/L mifepristone were named the Mifepristone group. HHUA cells co-transfected with pcDNA3.1-PI3K and pcDNA3.1-AKT overexpression vectors were treated with 100 μmol/L mifepristone and named the Mifepristone + PI3K/AKT group. mRNA expression was detected by quantitative reverse transcription PCR...
2018: OncoTargets and Therapy
Wen-Jian Liu, Yi-Bo Yin, Jing-Yi Sun, Sai Feng, Jin-Kui Ma, Xiao-Yan Fu, Ya-Jun Hou, Ming-Feng Yang, Bao-Liang Sun, Cun-Dong Fan
Background: Temozolomide (TMZ)-based chemotherapy represents an effective way for treating human glioma. However, its clinical application is limited because of its side effects and resistance to standard chemotherapy. Hence, the search for novel chemosensitizers to augment their anticancer efficiency has attracted much attention. Natural borneol (NB) has been identified as a potential chemosensitizer in treating human cancers. However, the synergistic effect and mechanism of NB and TMZ in human glioma have not been investigated yet...
2018: OncoTargets and Therapy
Chenghui Lin, Bin Gao, Xuemao Yan, Zixiong Lei, Kebing Chen, Yuquan Li, Qing Zeng, Zeqin Chen, Haomiao Li
Purpose: The purpose of this study is to evaluate the effects of miR-628 on migration and invasion of breast cancer stem cells (CSCs), which are essential for tumor recurrence and metastasis. Materials and methods: Quantitative reverse transcription-polymerase chain reaction was used to determine the expression of microRNAs and mRNAs. A subpopulation of CD44+ /CD24- breast CSCs were sorted by flow cytometry. Transwell assays were used to evaluate cell migration and invasion...
2018: OncoTargets and Therapy
Bing Zhao, Hang Xu, Xiaoye Ai, Yasheng Adalat, Ying Tong, Jiazhennan Zhang, Shune Yang
Purpose: This study aimed to analyze expression profiles of long noncoding RNAs (lncRNAs) in lung adenocarcinoma. Methods: lncRNA microarray technology was employed to detect lncRNA profiles of 3 pairs of lung adenocarcinoma tissues and adjacent tissues. Results: We found 134 upregulated lncRNAs and 460 downregulated lncRNAs in lung adenocarcinoma tissues compared to adjacent tissues. Among them, LINC00152, LINC00691, and LINC00578 showed the most significant changes of upregulation, while LINC00668, LINC00710, and LINC00607 showed the most significant changes of downregulation...
2018: OncoTargets and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"